-->

Tag: graft-versus-host disease

Home / Established Year

, , , , ,

Abatacept is approved for prophylaxis of acute graft versus host disease

March 2022: Abatacept (Orencia, Bristol-Myers Squibb Company) has been approved by the Food and Drug Administration for the prevention of acute graft versus host disease (aGVHD) in adults and paediatric patients 2 years of age an..

, , , , , ,

The FDA has approved belumosudil for the treatment of chronic graft-versus-host disease

August 2021: After failure of at least two prior lines of systemic therapy, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and paediatric patients 12 ye..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy